Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD
NCT07194590Phase 2
Key facts
- Status
- Recruiting
- Start
- Feb 2026
- Primary completion
- Nov 2030
- Countries
- 1
- Sponsor
- University of Colorado Denver
- Modality
- Small Molecules
- Drugs
- equol
- Conditions
- chronic kidney disease (CKD)
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Equol with Placebo (2 arms). Primary endpoint: Brachial Artery Flow-Mediated Dilation at 12 weeks. Started Feb 2026; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Equol
10 mg equol per day (2 capsules/day, 5mg equol/capsule)
Placebo
2 placebo capsules per day
03
Who it enrols
Postmenopausal women aged 50+ with stable CKD stage 3 or 4, low habitual soy intake, and stable weight. Excludes patients on dialysis, with uncontrolled hypertension, using hormone replacement therapy, or with a history of breast cancer or severe congestive heart failure.
04
Endpoints
Primary
Brachial Artery Flow-Mediated Dilation
Secondary
Carotid-Femoral Pulse Wave Velocity
Casual blood pressure
Beyond the preview
Go deeper on NCT07194590.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07194590.